Clinical Trial Update: A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating ESO-T01 for relapsed or refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ESO-T01

Snippet

Sponsor: Chunrui Li | Conditions: Relapsed/ Refractory Multiple Myeloma | EARLY_Phase 1 | Status: RECRUITING